The aim of this paper is to perform the first national analysis of demographic and clinicopathological features associated with HER2-positive, HER2-low, and HER2-zero invasive breast cancers across New Zealand, to estimate the proportion of women who stand to benefit from new targeted therapies for HER2-low and HER2-positive tumours. The gene discussed is ERBB2; the disease is invasive breast carcinoma.